naxitamab (Danyelza) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$15246.3200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

124i-humanized 3f8 | 131i-3f8 | 3f8 | hu3f8 | mab-3f8 | monoclonal antibody 3f8

Organizations (18)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Neuroblastoma (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Bone Marrow Cells (Phase 1)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 1/Phase 2)

Ganglioneuroblastoma (Phase 3)

Intestinal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 2)

Neuroblastoma (Phase 4)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Retinoblastoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 39
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue